GLOBAL-BLUE
21.4.2021 12:33:09 CEST | Business Wire | Press release
Global Blue, today, announced the launch of Global Blue Ventures, a new entity created to identify, invest in and/or partner with third parties that offer market-leading retail technology solutions.
Global Blue Ventures was initiated in 2019, and officially launched in April 2021, to advance Global Blue’s ambition to be a strategic omnichannel technology and payments partner empowering merchants to improve their performance.
Extending Global Blue’s value proposal with innovative omnichannel solutions
Global Blue Ventures concentrates on innovative and promising new businesses, with best-in-class companies selected to support brands on their omnichannel path.
The Ventures program will focus on add-on technologies that can easily integrate with retailers’ core systems, allowing them to:
- Optimise and digitalise their processes across the entire omnichannel customer journey: online, in store and at home
- Capture customers’ identity and engage with them on a personalised one-to-one basis
- Collect and cross-reference data to provide advisory services and actionable insights
It will focus its efforts on three key verticals and market needs:
- eCommerce: how to boost conversion rates and improve return efficiency
- Store digitalisation: how to digitalise in-store processes and experiences
- Clienteling 2.0: how to engage digitally one-to-one with consumers
RetailTech market experts James Strabo, previously a founding member and Managing Director at Blackhawk Network and Managing Director at Westfield (OneMarket), and Andrew Carroll, Founder of Yocuda and formerly Director of Corporate Development at Westfield (OneMarket) will lead Global Blue Ventures. Their mission will be to pinpoint latest retail market trends, identify the best-in-class technology players for each vertical, test and collect retailers’ feedback and, where appropriate, drive investments in the retail technology partners that can further accelerate Global Blue’s omnichannel market expansion.
Advancing with investment in promising new verticals
Since its inception, Global Blue Ventures has already enabled Global Blue to join forces with several leading players including:
- Yocuda: in October 2020, Global Blue acquired a minority stake in Yocuda, a leading digital receipt provider. Yocuda allows retailers to send content-rich, personalised digital receipts to consumers, whilst capturing data that allows for customer insight, management and engagement. Its technology can also be linked to a brand loyalty programmes. Yocuda is partnered with leading companies such as Marks & Spencer and Argos.
- ZigZag Global: in March 2021, Global Blue announced the acquisition of ZigZag Global, a leading Software-as-a-Service (SaaS) technology provider. ZigZag replaces the traditional paper-based “label in the box” returns solution with an online portal that enhances the experience for consumers and streamlines the process for retailers across the world. ZigZag is partnered with leading retailers such as Selfridges and Superdry.
Jacques Stern, CEO of Global Blue: “As a technology and payment partner for retailers, we are looking at extending our solutions on the full omnichannel journey, for both domestic and international shoppers. The network of RetailTech companies that we have started to create through Global Blue Ventures will enable us to co-create integrated solutions that achieve this goal and ensure we continue to meet our clients’ evolving needs.”
James Strabo and Andrew Carroll, Founding Partners of Global Blue Ventures: “ We are very pleased to be joining Global Blue and look forward to bringing our vision and expertise to help propel the business further into the RetailTech space. We are confident that the network of RetailTech partners we will build will give Global Blue clients access to the best-in-class solutions and will enable them to stay at the forefront of the latest omnichannel trends.”
ABOUT GLOBAL BLUE
Global Blue is a long-standing and trusted partner for retailers across the world. Its omnichannel technology and payments solutions empower its clients to improve their performance in the following areas:
- Tax Free Shopping: After pioneering the concept of Tax-Free Shopping more than 40 years ago, Global Blue’s integrated technology solutions at 300,000 points of sale offer 13 million international shoppers a seamless and personalised experience when claiming back the VAT on goods purchased abroad.
- Added Value Payment Solutions: Global Blue partners with more than 50 acquirers and Payment Service Providers across the world to provide retailers and hoteliers with a best-in-class FX solution that serves 16 million travellers and online shoppers at more than 130,000 points of interaction.
- Ecommerce returns: Global Blue offers, through its ZigZag Global brand, an enhanced, fully digital returns experience to more than 12 million domestic shoppers by connecting retailers to a network of more than 450 carrier services and 220 warehouses in 130 countries.
A unique understanding of shoppers and their shopping history enables Global Blue to provide Advisory Business Intelligence services, helping retailers to identify revenue and costs opportunities, while its Consumer Engagement solutions help retailers to capture growth opportunities.
In the financial year ending 31 March 2020, Global Blue processed 35 million Tax Free Shopping transactions with a total value of €18.5 billion sales in store, and 31 million Added-Value Payment Solutions transactions with a total value of €4.4 billion sales in store. Global Blue has almost 1,500 employees and is present in more than 50 countries.
Global Blue is listed on the New York Stock Exchange under the ticker GB.
For more information : globalblue.com/corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005512/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
